.png)
Magnolia Medical Technologies patented initial specimen diversion for blood culture collection, both the technique, ISDT®, and the technology, Initial Specimen Diversion Device® (ISDD®). Our mission is to improve the diagnostic accuracy and timeliness for sepsis testing to achieve better outcomes for all patients, reduce hospital costs, and battle the global threat of antibiotic resistance.
Magnolia Medical Technologies is on a Mission to ZERO™. Today, we offer healthcare institutions a solution to some of their biggest hidden problems – contamination leading to misdiagnosis of bloodstream infections, including sepsis, which can lead to unnecessary and prolonged antibiotic therapy, and false-positive CLABSIs. Tomorrow, we aspire to create a world free of in-vitro diagnostic errors where rapid, accurate test results improve the lives of patients and providers alike.
We know that setting new standards of care is a journey enabled by purposeful innovation, partnerships, and perseverance. As the first step of our journey, we have successfully developed and proven our evidence-based technology platform, Steripath, which we’ve coupled with unparalleled support to change clinical practices and prevent unnecessary patient harm as well as system-wide costs associated with the misdiagnosis of sepsis.
Our mission is further enabled by reducing false-positive CLABSIs and leveraging our extensive intellectual property portfolio – consisting of over 100 issued method, apparatus, and design patents and 70+ patent applications pending – to address other important sources of diagnostic error that are harmful to patients and costly to hospitals.